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tabolites emerging thereof for each individual. Great hopes 
are currently associated with systems biology to cover these 
demands in time (i.e. along the pathogenesis) and space (i.e. 
in all relevant tissues).  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Personalized medicine – or the use of information 
about a person’s genes, proteins, metabolites and envi-
ronment to prevent, diagnose and treat disease – has been 
much talked about in recent years. And some observers 
are wondering what the excitement is all about, cumulat-
ing in the following statement: ‘Personalized healthcare 
is nothing new. Doctors have always tried to fit the ther-
apy to the patient if possible. But what’s happened more 
recently is that we have begun to go a level deeper. We are 
now exploring the biology of disease and treatment at the 
molecular level.’ Molecular medicine does not per se de-
fine personalized medicine, but molecular tools are im-
portant as they should enable greater relevance of the in-
formation provided by diagnostic tests. As ‘personalized’ 
means different things to different people, additional 
complementary ways of characterizing diagnostics may 
further help distinguish different shades of gray in the 
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 Abstract 
 Typical civilization diseases, such as type 2 diabetes, share 
several features: their worldwide frequency, the complexity 
of the underlying pathogenic mechanisms, heterogeneity in 
the phenotypes and their multifactorial nature due to a wide 
variety of possible combinations of disease susceptibility or 
protective genes in different tissues and negative or positive 
environmental factors. This is in sharp contrast to classical 
inherited diseases, such as Huntington’s chorea, which are 
often caused by complete loss- or gain-of-function muta-
tions in a single gene. The causative polymorphisms of sus-
ceptibility genes, however, are characterized by relatively 
subtle alterations in the function of the corresponding gene 
products, i.e. low penetrance and effect size, which do not 
support the pathogenesis per se, and by their high frequen-
cy; these two characteristics result in high expenditures for 
their identification and a rather low predictive value. In the 
future, the reliable and early diagnosis of common diseases 
will thus depend on the determination of all (or as many as 
possible) polymorphisms of each susceptibility gene to-
gether with the corresponding gene products and the me-
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spectrum of personalized medicine. In the strictest sense, 
personalized-medicine diagnostics may consist exclu-
sively of companion diagnostics, which are by definition 
geared towards supporting a therapy decision for a par-
ticular drug, patient by patient. At a more permissive end 
of the spectrum, personalized-medicine tests may in-
clude: (1) early diagnostics, which encompasses diagnos-
tic products permitting the detection of a disease at very 
early stages of its development and thus gives more treat-
ment options; (2) prognostics, which means diagnostics 
that predict or estimate the risk of developing a particular 
condition based on phenotypic (e.g. transcriptomic, pro-
teomic or metabolomic) parameters or genomic (e.g. he-
reditary or gene-based) characteristics, and (3) all other 
types of diagnostics. One may indeed argue that if a di-
agnostic were not designed to inform treatment decisions 
for individual patients – one way of defining a personal-
ized-medicine diagnostic – it would not make much 
sense.
 Drug approval agencies, including the Federal Drug 
Administration (FDA) and the European Medicines 
Agency (EMEA), are encouraging greater use of bio-
markers and diagnostics in drug development and pre-
scribing decisions, thus promoting the concept of com-
panion diagnostics for drugs. The FDA has recently start-
ed reporting a list of genomic biomarkers that it considers 
valid to guide the appropriate clinical use of approved 
drugs. The list is being updated on a quarterly basis and 
counted 32 valid genomic biomarkers in mid-September 
2009. Most drug labels in the list provide pharmacoge-
nomic information with no immediate recommendation 
for genetic testing. However, testing is ‘recommended’ or 
‘required’ in a few cases. On March 20, 2009, four bio-
markers were ‘required’ to be tested – three for cancer, 
and one for infectious disease indications.
 We are still at the start of the process if we consider 
that only four biomarkers are ‘required’ to be tested. 
However, the FDA was prompted to publish its list follow-
ing a marked increase in the number of approved drug 
labels containing pharmacogenomic information over 
the last decade. The FDA estimates that 10% of approved 
drug labels now contain pharmacogenomic information 
and this is expected to continue increasing. The EMEA’s 
communication on the requirement for biomarker test-
ing is less transparent than the FDA’s, but its initiatives 
should not be overlooked. For example, the EMEA played 
a key role in requiring biomarker testing for Amgen’s 
Vectibix (active principle panitumumab, human mono-
clonal antibodies against epidermal growth factor recep-
tor), following the FDA’s accelerated approval without 
specific testing requirements. The EMEA also requires 
biomarker testing for a larger number of drugs: in mid-
2009 accounting for at least 11 such drugs. Greater har-
monization between regulatory agencies has to be devel-
oped over time through greater consultation but also
following pressure from clinician communities as stake-
holders in one country push to implement practices al-
ready included in drug labels in other countries.
 Type 2 Diabetes – The Pathogenesis of a Common 
Disease 
 Meanwhile, 5–10% of the individuals over 40 years of 
age in the Western world will suffer from diabetes during 
their lifetime, with increasing tendency. Most of them 
(about 95%) suffer from type 2 diabetes with late-onset 
clinical manifestations in most cases. A minor portion is 
affected by type I diabetes, often fully developed already 
between the 15th and 25th year of life and most likely 
completely different from that of type 2 diabetes  [1, 2] . 
Due to the serious and long-lasting consequences for the 
individual’s fate and welfare, the reliable and early diag-
nosis as well as the efficacious and safe therapy of type 2 
diabetes is of tremendous importance for the patients as 
well as for the national health care systems.
 Frank type 2 diabetes is characterized and caused by 
excessively high blood glucose levels already in the fast-
ing state and even higher levels in the postprandial state 
( fig. 1 ). After consumption of carbohydrate-rich food 
(e.g. 75 g chocolate), the glucose absorbed by intestinal 
cells is released into the circulation, resulting in the tran-
sient increase in blood glucose levels for about 1 h. There-
after, the glucose is removed from the blood into the pe-
ripheral tissues, predominantly muscle, fat and liver 
( fig. 1 ), and stored after conversion to glycogen and lipid, 
resulting in a decline in blood glucose levels to almost 
fasting levels after 2 h. In the course of type 2 diabetes, 
utilization of the blood glucose (glucose disposal) by the 
peripheral tissues is significantly impaired and, conse-
quently, glucose accumulates in the circulation. Initially, 
elevated blood glucose is not accompanied by clinical in-
sults, one could argue – unfortunately – given the miss-
ing chance of early diagnosis, before the manifestation of 
irreversible pathogenic mechanisms. However, elevated 
blood glucose leads to damage to certain proteins from 
the very beginning. During exposure to high glucose 
concentrations, a variety of extra- and intracellular pro-
teins – in particular long-lived serum, matrix and cyto-
skeletal proteins – become covalently coupled to glucose 
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and some of its derivatives ( fig. 2 , hyperglycemia). This 
spontaneous nonenzymic glycation of proteins, which is 
diagnostically monitored with the biomarker hemoglo-
bin A1c (HbA1c), impairs their function irreversibly. 
Over the years (5–25 years), relevant cells and tissues
will become increasingly damaged and trigger diabetic 
late complications. These predominantly affect the eyes 
(blindness), kidneys (renal failure), peripheral nervous 
system (pain), brain (mental problems), small vessels 
(atherosclerosis, ischemia, stroke) and large vessels 
(thromboses, amputations) ( fig. 2 ). Despite intensive ef-
forts in diagnosis and therapy, type 2 diabetes is current-
ly still associated with considerable reductions in life 
quality and life expectancy.
 What are the reasons for the reduced glucose disposal 
by the peripheral tissues, which ultimately results in dia-
betic late complications caused by elevated blood glucose 
levels? For proper glucose disposal, the peripheral tissues 
depend on endocrine signals, in particular insulin, the 
blood glucose-regulating hormone ( fig. 1 , arrows). The 
pancreatic beta cells function as sensors for blood glucose 
and respond with the production and secretion of insu-
lin. In addition, the beta cells receive direct hormonal in-
formation (e.g. glucagon-like polypeptide-1) on the 
amount of glucose just taken up with the food from spe-
cial intestinal cells, which also operate as glucose sensors 
( fig. 1 , arrow). The insulin released by the beta cells into 
the circulation tells the muscle, adipose and liver cells to 
take up the glucose and convert it to glycogen and/or lip-
ids. This metabolic insulin action requires a multitude of 
components for intracellular signaling and the terminal 
transport steps and enzymic pathways  [1–3] . Defects in 
those components of glucose sensing, insulin production 
and secretion, or insulin action in the glucose-sensing or 
utilizing cells will inevitably result in inadequate and de-
layed glucose disposal from the circulation and concom-
itantly impaired glucose tolerance. Thus impaired glu-
cose disposal may be caused by defects ( fig. 1 , crosses) in 
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the beta cells or intestinal cells affecting glucose sensing, 
in the beta cells affecting insulin production and secre-
tion and in the muscle, adipose and liver cells affecting 
insulin action. Each of these processes depends on a mul-
titude of genes and gene products including signaling 
proteins and terminal effector proteins, such as the glu-
cose transporter, glucokinase, ATP-dependent potassi-
um channel (K ATP SUR1/Kir6.2) for glucose sensing by 
the beta cells and insulin itself for insulin production by 
the beta cells as well as the insulin receptor with its iso-
forms A and B, insulin receptor substrate proteins 1–4 
and Gab-1), glucose transporter protein-4, pyruvate de-
hydrogenase, acetyl-CoA carboxylase, glycogen synthase 
and glycerol-3-phosphate acyltransferase for insulin ac-
tion in the muscle, adipose and liver cells ( fig. 3 ). It is cur-
rently estimated that 5–10% of the human genes, i.e. 
1,500–3,000, are directly or indirectly involved in glucose 
disposal and regulation  [4] . In principle, each of these 
genes is a candidate for a so-called disease gene and/or 
susceptibility gene for type 2 diabetes, i.e. functional al-
terations may lead to impaired glucose disposal.
 Disease Genes 
 Any variant (i.e. polymorphism or mutation) of a (pu-
tative disease or susceptibility) gene coding for a protein 
may affect its promoter, exon, intron or terminator areas 
with varying functional consequences involving differ-
ent molecular mechanisms (single nucleotide exchange, 
duplication, insertion, translocation, inversion, deletion) 
( fig. 4 ). If they are located in exons or at exon-intron 
boundaries, they will directly affect the structure of the 
protein in most cases and thereby lead to drastically re-
duced or, in rare cases, increased activity. If they are lo-
cated in introns or promoter regions, they will cause 
Insulin 
receptor A/BGlucose
MEKK
Mek
Akt aPKC
GSK3PP1p70rsk
PI3K
PTEN
SHIP2
MAP kinase
GLUT4
Glucose
transport
Cell growth
differentiation
General gene
expression
GLUT4
PDH  ACC  GS  GPAT
Glucose metabolism
Glycogen synthesis
Lipid synthesis
Specific gene expression
 Fig. 3. Molecular mechanisms for the stimulation of glucose uti-
lization by insulin in muscle, liver and adipose cells. The binding 
of insulin to the insulin receptor triggers autophosphorylation 
and activation of the intrinsic tyrosine kinase which in turn phos-
phorylates the adaptor proteins IRS1–4 and Gab-1. Their interac-
tions with signaling proteins activate at least three signal trans-
duction cascades, such as the Cbl/CAP, PI 3 K/Akt and Ras/MAP 
kinase pathways, which control the vesicular trafficking of glu-
cose transporter protein-4 (GLUT4) from intracellular vesicles to 
the plasma membrane, the activity of rate-limiting enzymes of 
glucose and lipid metabolism, such as pyruvate dehydrogenase 
(PDH), acetyl-CoA carboxylase (ACC), glycogen synthase (GS) 
and glycerol-3-phosphate acyltransferase (GPAT), and the specif-
ic and general gene expression. Together, this leads to the uptake 
of glucose and its metabolism to glycogen and lipid in response to 
insulin in relevant glucose-utilizing tissues upon their adequate 
growth and differentiation, which is also regulated by insulin-
dependent gene expression. Only some of the major signaling and 
terminal effector proteins are shown.  
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drastically reduced or, in rare cases, increased protein 
synthesis. Moreover, monoallelic expression and variants 
in the copy number of genes may contribute to an enor-
mous diversification of the human genome with corre-
sponding phenotypic consequences ( fig. 4 ). With the 
complete description of all integration sites of the most 
frequent copy number variants and the introduction of 
novel methods for their identification and characteriza-
tion in the total genome, it should be possible to evaluate 
the physiological relevance of copy number variants of 
disease genes (and susceptibility genes, see below) to the 
pathogenesis of type 2 diabetes. All these polymorphisms 
and mutations may already be manifested in the germ 
line cells and may thus be inherited or occur in a subset 
of somatic cells during life.
 On the basis of our knowledge of the molecular mech-
anisms of blood glucose regulation, it is tempting to spec-
ulate on polymorphisms or mutations in single but essen-
tial genes for glucose disposal that represent the primary 
cause of type 2 diabetes. In fact, it has been known for 
more than 100 years, since Sir Archibald Garrod’s  Inborn 
Errors of Metabolism, that the complete defect of a single 
gene product, for instance phenylalanine hydroxylase, 
can lead to severe metabolic diseases, such as phenylke-
tonuria. Subsequently, typical mendelian inheritance, i.e. 
monogenic inheritance, has been delineated for a number 
of human diseases from family studies  [5, 6] . There has 
been rapid progress in defining the etiological genes for 
monogenic diabetes, which reflects the relative simplicity 
of gene discovery in single-gene disorders. The candidate 
gene approach has been remarkably successful in defin-
ing monogenic diseases. This reflects that key rate-limit-
ing steps in insulin secretion and action are known, and 
severe mutations affecting these processes and the under-
lying proteins will result in beta cell dysfunction or insu-
lin resistance. Examples of this approach include the 
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genes encoding insulin  [7] , glucokinase  [8, 9] , the two 
subunits of K ATP Kir6.2  [10] and SUR1  [11, 12] , the per-
oxisome proliferator-activated receptor PPAR   [13] , and 
the insulin receptor with its isoforms A and B  [14] . Find-
ing human subjects with mutations in these candidate 
genes has allowed confirmation of a critical role in hu-
mans of the encoded protein, helped define the structure 
and function of the protein and allowed confirmation of 
the associated pathophysiology, such as abnormal glu-
cose sensing in glucokinase mutations  [15] . In fact, single 
mutations in the genes coding for insulin receptor A/B or 
glucokinase have subsequently been identified in patients 
with severe phenotypes, so-called leprechaunism and 
maturity-onset diabetes of the young type 2 (MODY2)  [3, 
4] . In addition to the missing regulation of the blood glu-
cose, the affected patients suffer from severe growth and 
developmental retardation. The presence of one copy of 
the polymorphic/mutant gene coding for the insulin re-
ceptor or glucokinase suffices for both diseases to mani-
fest themselves, i.e. they are dominantly inherited. How-
ever, the candidate gene approach has not led to the iden-
tification of novel pathways in glucose homeostasis.
 Completely unexpected pathways critical for insulin 
secretion and action were identified by pedigree analysis 
of the association of a phenotype with a genetic marker 
within affected families or populations, i.e. positional 
cloning of novel monogenic type 2 diabetes genes. The 
most striking example was the identification of the tran-
scription factor, hepatic nuclear factor 1A  (HNF1A), as 
the gene linked to the phenotype of MODY and mapped 
to chromosome 12q  [16] . Before this finding, it was not 
known that  HNF1A  was expressed in the beta cell, and 
diabetes had not been noticed in the  hnf1  -knockout 
mouse  [17] , although it was noticed subsequently  [18] . 
This result rapidly led to the detection of mutations in 
other hepatic transcription factor genes,  HNF4A  [19] and 
 HNF1B  [20] , also shown to cause MODY. These findings 
have led to a totally new area of beta cell biology seeking 
to explain why haploinsufficiency of these genes resulted 
in progressive beta cell dysfunction  [21, 22] . Other mono-
genic defects in glucose utilization, such as leprechaun-
ism, are recessively inherited, i.e. they only become man-
ifest in the presence of both maternal and paternal copies 
of the disease gene, such as mutations in the insulin re-
ceptor. Mutations in the gene encoding the lipolytic en-
zyme carboxyl-ester lipase, which is responsible for the 
hydrolysis of cholesterol esters, were also unexpectedly 
found to cause distinct MODY phenotypes through po-
sitional cloning  [23] . Carboxyl-ester lipase is only ex-
pressed in the pancreatic acinar cells, so beta cell dys-
function was unexpected. Further studies of the mecha-
nism will clarify the close relationship between the 
exocrine and endocrine pancreas. Following mapping to 
chromosome 1q21, familial partial lipodystrophy was 
shown, to arise from mutations in the  LMNA  gene, en-
coding lamin A/C  [24] . Mutations in  LMNA can also re-
sult in myopathy, dilated cardiomyopathy, or atypical 
progeria  [25] ; the biology of how these mutations alter fat 
distribution is still incompletely understood. In addition, 
for many genetic syndromes, such as Wolcott-Rallison 
and immune dysregulation, polyendocrinopathy, enter-
opathy, X-linked syndromes, a discrete cluster of clinical 
features including diabetes was initially recognized as a 
clinical syndrome and subsequently the responsible gene 
was identified  [26, 27] . In these cases, discovery of the 
gene gave new biological insights but only limited in-
sights into the phenotype. Nevertheless, taken together 
positional cloning has led to exciting novel pathways of 
glucose homeostasis.
 A key result has been that the vast majority of genes 
single mutations of which cause early-onset diabetes ex-
ert reduced beta cell function rather than increased 
 insulin resistance. Heterozygous haploinsufficiency re-
sults in dominant early-onset diabetes for many beta cell 
genes, including  GCK, HNF1A, HNF4A, and  HNF1B, but 
this is not seen in insulin resistance genes. This shows 
that even when faced with severe insulin resistance, a 
healthy beta cell is usually able to compensate, but no 
compensation is possible in the presence of marked in-
sulin deficiency. There are many mechanisms of beta cell 
dysfunction in monogenic diabetes, including reduced 
beta cell development, failure of glucose sensing, and in-
creased destruction of beta cells. Importantly, individu-
als with type 2 diabetes typically display concomitant 
defects in both insulin secretion and action. While it is 
axiomatic that hyperglycemia implies some degree of 
relative or absolute failure of beta cell function, there has 
been a long-standing debate about the relative impor-
tance (even ‘primacy’) of the two processes in the patho-
genesis of type 2 diabetes. Notwithstanding the efforts of 
epidemiologists and physiologists, this may be one de-
bate where genetics in general and positional cloning in 
particular (precisely because of the focus on inherited 
rather than acquired phenomena) may provide the 
 answers. The relative prevalence of mutations causing 
monogenic forms of diabetes suggests that mutations in 
beta cell-related processes are a more frequent cause of 
severe early-onset diabetes than mutations influencing 
insulin action. Studies of the relative heritability of in-
dexes of beta cell function and insulin action in the gen-
 Müller Pharmacology 2010;85:168–187174
eral population also suggest a preponderance of beta cell 
effects  [28] .
 However, the drastic and relatively homogeneous phe-
notypes with rather early-onset and complete or at least 
partial independence of the environment, as in lepre-
chaunism and MODY, is characteristic for disease genes, 
such as mutations in the  IRA/B and  HNF4A genes. The 
underlying (almost) complete absence in the function or 
synthesis of the relevant gene product ( fig. 4 ) is, however, 
very rare and apparently not causative of typical type 2 
diabetes, with its frequent and late manifestations and its 
rather moderate, nevertheless harmful phenotype of con-
siderable heterogeneity and dependence on the environ-
ment. Monogenic and syndromic forms account for only 
a small though highly informative proportion of cases of 
nonautoimmune diabetes. The challenge for medical sci-
ence lies in bringing equivalent mechanistic insights and 
translational benefits to the hundreds of millions of peo-
ple already affected by type 2 diabetes or at risk. There is 
abundant evidence that individual susceptibility is influ-
enced by both the combination of genetic variation at 
multiple sites and a series of environmental exposures 
 [28] . Tracking down the specific genetic variants involved 
has been more difficult than for monogenic forms of the 
disease since the correlations between genotype and phe-
notype are far weaker.
 Susceptibility Genes 
 In fact, most patients with type 2 diabetes harbor ful-
ly functional insulin receptors, glucokinases or HNF 
transcription factors and transmission from generation 
to generation apparently does not obey mendelian laws. 
Pedigree analysis typically reveals ( fig. 5 ) that healthy 
parents have affected offspring and vice versa. Neverthe-
less, an increased frequency of type 2 diabetes can often 
be derived from most pedigrees of affected twins, fami-
lies and populations. The concordance rate for type 2 di-
abetes is about 70% for monozygotic and 20–30% for di-
zygotic twins in comparison to 10% as commonly ob-
served for Western populations. The individual risk for 
the development of type 2 diabetes in a lifetime accounts 
for about 40% in case of individuals with either an af-
fected father or an affected mother, with a trend to a high-
er risk in case of an affected mother; the risk approaches 
70% in case of both parents suffering from the disease. 
Moreover, first-degree relatives of type 2 diabetics are 
faced with a three-fold elevated disease risk compared to 
nonrelatives. The pronounced ethnic differences in the 
frequency of type 2 diabetes, which have been known for 
decades, may also be indicative of a genetic component. 
Studies of large series have shown that the known type 2 
diabetes susceptibility variants (see below) influence 
clinically relevant phenotypes, such as disease progres-
sion  [29] , risk of complications and therapeutic response 
 [30] . However, it does not follow that those differences 
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 Fig. 5. Identification of disease and susceptibility genes by positional cloning. 
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suffice to provide clinically information relevant to indi-
vidual patients. Indeed, the modest effect sizes of the 
variants identified to date mean that their individual im-
pact is likely to be limited. This is best illustrated by con-
sidering variants in  TCF7L2  [30, 31] . Genome-wide asso-
ciation (GWA) studies have demonstrated that variants of 
this gene have the strongest effect on diabetes risk cur-
rently known (see below). Assuming an average lifetime 
risk of type 2 diabetes of about 10%, this percentage 
would decrease to about 7.5% in an individual with no 
copies of the risk allele, whereas the lifetime risk of an 
individual with two copies would increase to 14.5%. Tak-
en together, there is no doubt about a strong genetic back-
ground for type 2 diabetes, i.e. about the operation of sus-
ceptibility genes in the affected twins, families and popu-
lations during its pathogenesis. This holds true for the 
majority of the typical complex and multifactorial ‘civili-
zation’ diseases, among them cardiovascular and (neuro)-
degenerative diseases as well as the most common types 
of cancer. During the past 50 years of the worldwide epi-
demic increase in the number of type 2 diabetic patients, 
our  environmental conditions have changed to the typi-
cal Western lifestyle of permanent food availability and 
physical inactivity. Our genes, however, have not changed 
to any significant degree during this period. This does 
not exclude an important role of the genes involved in 
glucose utilization and of their polymorphisms in the 
current, rapidly increasing prevalence of type 2 diabetes 
since they ultimately determine the response of our or-
ganism to the altered lifestyle.
 Identification of Disease and Susceptibility Genes 
 The traditional method for the identification of dis-
ease and susceptibility genes relevant to the rare mono-
genic and common polygenic diseases is linkage analysis. 
However, the chromosomal regions identified by linkage 
analysis of several thousand families, which segregate the 
relevant gene locus, typically exceed 30 cM in length and 
may contain several hundred genes. In the past, those ex-
tended chromosomal regions were associated with the 
pathogenesis of certain multifactorial diseases, such as 
cancer and asthma, in the course of linkage analyses us-
ing pronounced structural chromosomal aberrations, 
such as deletions, inversions, duplications or transloca-
tions. Subsequently, positional cloning was used for fine 
mapping. For this, as the first step, the gene apparently 
associated with the disease is attributed to a limited re-
gion within a chromosome (preferably less than 1 cM = 
1% recombination frequency) during sequential rounds 
of linkage analysis of a genetic marker and a phenotype 
within affected family pedigrees. The genetic marker 
may be located in the immediate neighborhood of the 
disease gene rather than within it. If appropriate, the cop-
ies of highly repetitive satellite DNA with often unknown 
structural or regulatory function are used as genetic 
markers for linkage analysis. In the next step, each posi-
tional candidate assigned to a given chromosomal inter-
val will be tested for its functional relevance to the patho-
genesis of the disease in biochemical and cell biological 
experiments and for the existence of the relevant poly-
morphisms/mutations in affected families and popula-
tions in epidemiological studies.
 For monogenic diseases, linkage analysis and posi-
tional cloning often lead to the unambiguous delineation 
of the underlying disease gene. However, so far the use of 
those strategies for the identification of susceptibility 
genes for complex multifactorial common diseases has 
been of only limited success  [32, 33] . This is certainly due 
to the typically rather limited causal relationship between 
the mutations or polymorphisms of a single gene and the 
resulting phenotype. In the example of  figure 5 , satellite 
DNA is closely associated with the susceptibility gene and 
therefore used as genetic marker for the prevalent poly-
morphisms ‘1–4’. Among them, the predisposing poly-
morphism ‘3’ is associated with three copies of the satel-
lite DNA, the other nonpredisposing polymorphisms ‘1’, 
‘2’ and ‘4’ are also linked to this satellite DNA, but in dif-
ferent copy numbers each. The copy numbers are deter-
mined via amplification of the complete satellite DNA by 
polymerase chain reactions using appropriate primers 
and subsequent analysis of its migration behavior (and 
thus its length) by gel electrophoresis ( fig. 5 ). According-
ly, 4 type 2 diabetic patients harbor polymorphism ‘3’ (2 
homozygous, 2 heterozygous), 2 patients have polymor-
phism ‘1’ or ‘2’ and ‘4’ and 2 healthy probands have poly-
morphism ‘3’ (homozygous, heterozygous). This analysis 
demonstrates that the association of polymorphism ‘3’ 
with type 2 diabetes is higher compared to a random dis-
tribution. However, there are carriers of polymorphism 
‘3’ who apparently are not affected by the disease and vice 
versa. In consequence, the disease risk for carriers of 
polymorphism ‘3’ is considerably higher than for noncar-
riers; however, far away from the 100% as holds true for 
monogenic diseases. Apparently, one or several addition-
al susceptibility genes are implicated in the pathogenesis 
but are not associated with the genetic marker used (here 
satellite DNA). This limited association of a single poly-
morphism with a phenotype is typical for susceptibility 
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genes. Carriers of the polymorphism may or may not be-
come affected by the disease; however, their relative risk 
for developing the disease is higher than for noncarriers, 
albeit the difference (i.e. effect size) may be very small (see 
below).
 This complexity inherent in the identification of dis-
ease and susceptibility genes by linkage analysis and po-
sitional cloning caused many researchers to favor the 
 alternative approach of directly studying the biological 
function of the candidate gene (‘candidate gene ap-
proach’). However, this strategy turned out to be rather 
disappointing too, mainly due to the often insufficient 
knowledge of the molecular mechanisms underlying the 
pathogenesis of multifactorial diseases. As a consequence, 
it appears that in many cases the candidate genes have 
been chosen in a rather arbitrary and biased fashion.
 In contrast, the identification of susceptibility genes 
by analysis of linkage disequilibrium is based on the de-
termination of the allelic distribution in distinct popula-
tions delineating the recognizable consequences of not 
recognizable recombination events along the historic de-
velopment of the population  [34] . In general, the identi-
fication of susceptibility genes by linkage disequilibrium 
is more precise and reliable compared to that by linkage 
analysis provided that the genetic marker used is located 
in the immediate neighborhood. The extent of linkage 
disequilibrium within populations typically encompass-
es 10,000–50,000 base pairs, which is 1,000-fold less than 
observed within families, enabling a much more precise 
and reliable localization of susceptibility genes. Conse-
quently, a successful strategy for the mapping and iden-
tification of susceptibility genes for complex multifacto-
rial diseases may rely on the initial rough linkage analysis 
for determination of chromosomal regions associated 
with a certain probability threshold. Subsequently, after 
successful replication of the findings on the basis of ad-
ditional human populations and independent data sets, 
the chromosomal regions with the strongest linkage are 
used for a more precise localization via analysis of the 
linkage disequilibrium. If the gene loci studied do not 
show pronounced heterogeneity and if a set of genetic 
markers of sufficient density is used, preferably single-
nucleotide exchanges, the signal of association of a linked 
chromosomal region will be of sufficient strength and 
can easily be detected. This approach has already led to 
the identification of a number of susceptibility genes. But 
its broad application for common diseases and major 
health problems, in general, is hampered by the enor-
mous expenditure for the adequate analysis of linkage 
disequilibrium covering large chromosomal regions.
 In addition, two technical problems seriously reduce 
the value of many association studies performed on the 
basis of linkage analysis or linkage disequilibrium  [32, 
35] . These studies have to be performed on populations 
which are representative for future prediction based on 
analysis of their genetic profile. Study protocols relying 
on the comparison of affected and nonaffected probands, 
such as those designed for case-control studies, should 
not be used to calculate the predictive value of certain 
combinations of susceptibility genes. In particular, as a 
consequence of selection, the affected probands may be 
overrepresented versus the healthy population. This is of-
ten the case in studies designed for the detection of dis-
ease or susceptibility genes by association. Genetic pro-
files (as well as traditional risk factors, see below) should 
preferably be examined in large cohort and longitudinal 
study populations in which disease prediction is intended 
to be performed in the future. Furthermore, the predic-
tive value is generally overestimated if the identification 
of a single polymorphism or a combination of polymor-
phisms for one or several susceptibility genes has been 
derived from the same study population. It is therefore of 
major importance that the results of GWA studies be re-
produced with at least one additional independent popu-
lation prior to publication.
 The successful elucidation of the association through 
linkage analysis or linkage disequilibrium does not neces-
sarily imply a causal relationship between the susceptibil-
ity gene and the disease. Linkage or linkage disequilibrium 
relies on a close neighborhood of gene loci, which reduces 
the probability of segregation by homologous recombina-
tion. However, it may persist over generations by chance 
rather than as a consequence of tight mechanistic coupling 
between susceptibility gene(s) and the pathogenesis. It is 
therefore of tremendous importance to demonstrate cau-
sality in subsequent biochemical, cell-biological and ani-
mal studies concerning the molecular mechanism that 
translates genetic information into a disease phenotype 
 [35] . For this, manipulation of the expression of disease or 
susceptibility genes using overexpression, silencing, trans-
genic and knockout approaches are of particular value.
 Despite these difficulties, 18 susceptibility genes for 
type 2 diabetes have been identified during the last de-
cade with the help of the methods described  [1–4, 6, 34] . 
However, they account for only about 1% of the theoreti-
cal number (see above). Additional susceptibility genes 
will certainly be detected in the near future. Some of the 
genes reported so far are shown in  figure 6 . They are dis-
tributed over the complete genome, i.e. 23 chromosomes 
and the mitochondrial DNA, with polymorphisms pre-
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dominantly encompassing single-nucleotide exchanges 
(but also other molecular mechanisms) in exons, introns, 
promoters and terminators ( fig. 4 ). Interestingly, the ma-
jority of the susceptibility genes are specifically expressed 
in the beta cell, a few of them in muscle, adipose and liv-
er tissues, which resembles the distribution of disease 
genes for monogenic type 2 diabetes (see above). Most 
importantly, the relative contribution of the  TCF7L2 
gene – for which the most significant disease association 
so far has been reported in several independent studies – 
to the development of type 2 diabetes has been estimated 
at only 34%. As the absolute risk of developing type 2 
diabetes is about 10% in Western populations, the indi-
vidual risk for carriers of the  TCF7L2 polymorphism in-
creases to about 13%. Moreover,  TCF7L2 and many of the 
other polymorphisms are present in the total population 
at a relatively high frequency. Both characteristics, i.e. a 
limited contribution to the individual disease risk (effect 
size) and pronounced frequency, are typical for the risk 
alleles of susceptibility genes. In contrast, carriers of the 
rare risk alleles of disease genes are faced with a theoret-
ical disease risk of 100%.
 Of course, individual small effect sizes can amount to 
more when considered collectively, and it is true that ge-
netic testing (for the known 18 genes) can identify subsets 
of individuals who have inherited particularly high or 
low numbers of risk alleles and therefore markedly differ 
in individual risk  [36] . However, the numbers of individ-
uals in these ‘extreme’ high- and low-risk groups are 
comparatively small, and in many, their risk will already 
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be obvious from conventional factors (e.g. family history, 
BMI, previous gestational diabetes, see below). When the 
information from the known type 2 diabetes susceptibil-
ity variants is examined using approaches such as receiv-
er-operating curve analysis, which are better suited for 
evaluating the performance of diagnostic tests at the pop-
ulation level, the results look far less spectacular.
 As mentioned above, success in the identification of 
disease and susceptibility genes impacting on individual 
risk of type 2 diabetes has come from two distinct ap-
proaches of gene discovery. The first, linkage mapping 
within monogenic and syndromic families, has identified 
rare but highly penetrant causal variants. The second, 
large-scale association mapping, is now yielding growing 
numbers of common variants. These have modest effect 
sizes and low penetrance, at best. Several genes have fea-
tures that were unraveled by both approaches. For ex-
ample, mutations in  KCNJ11, PPARG, WFS1, and  HNF1B 
are causal for syndromic variants and/or monogenic 
forms of diabetes, while common variants in these same 
genes influence predisposition to typical type 2 diabetes. 
While common variants in glucokinase do not influence 
type 2 diabetes risk per se, they have a clear impact on 
fasting glucose levels within the population. In any case, 
the genotype-phenotype relationships revealed by these 
gene discovery efforts will highlight the pathways in-
volved as prime candidates for beneficial therapeutic or 
preventative manipulation, a view reinforced by the fact 
that at least two of the genes involved in both monogenic 
and multifactorial forms of diabetes  (PPARG, KCNJ11) 
encode the targets of the two major classes of the cur-
rently available antidiabetic drugs, the thiazolidinedi-
ones and sulfonylureas, with the most widely used repre-
sentatives rosiglitazone and glimepiride  [37] . The corre-
sponding gene products, transcription factor PPAR  in 
adipose cells and the SUR1 subunit of the K ATP in pan-
creatic beta cells, play critical roles in the insulin-stimu-
lated whole-body glucose utilization and the glucose-
stimulated insulin secretion, respectively. However, it is 
remarkable that the associations of the corresponding 
polymorphisms  (PPARG P12A, KCNJ11 E23K) with type 
2 diabetes are relatively weak.
 It is obvious that the two ‘flavors’ of polymorphism – 
rare and highly penetrant on the one hand and frequent 
and low penetrant on the other – are not the only options 
when it comes to the variants that might influence disease 
susceptibility. It seems probable, even highly likely, that 
between these extremes there is a class of medium fre-
quency, medium penetrance variants that have escaped 
the gaze of the gene mappers until now. The penetrance of 
such variants would be too low to generate mendelian pat-
terns of segregation and the frequencies would be too low 
to be covered by current GWA approaches. Despite this, 
such variants have particularly attractive translational 
properties. For example, a variant the risk allele of which 
has a frequency of 1% and produces in a per-allele OR of 
about 3 would provide greater predictive power than the 
known variants in  TCF7L2. Polymorphisms with such 
characteristics are increasingly being reported in other 
disease states, such as breast cancer and hyperlipidemia 
 [38, 39] , and have even been reported in type 2 diabetes 
 [40] . In principle, just 30 such variants across the genome 
could explain the observed familial aggregation of type 2 
diabetes much better than the current set of common, low-
penetrance polymorphisms. Such a pool of polymor-
phisms would also provide an excellent tool for individual 
diabetes risk prediction, generating a discriminative ac-
curacy on receiver-operating characteristic analysis close 
to 80%. The advent of new high-throughput sequencing 
technologies, along with large-scale association analysis, 
brings variants in this class within reach of genetic discov-
ery and should allow researchers to evaluate the contribu-
tion to disease susceptibility attributable to polymor-
phisms that lie between the extremes, where attention has 
previously been focused. Many other challenges are to be 
faced and opportunities to be realized in the years ahead. 
The first of these consists in extending the range of poly-
morphisms that are accessible to scrutiny, beyond the low-
frequency variants referred to above, to a systematic eval-
uation of structural polymorphisms (insertions, deletions, 
translocations and duplications) and variants that influ-
ence the methylation status  [41] . Another lies in character-
izing the association signals that have been found. Large-
scale resequencing and fine-mapping strategies will be re-
quired to recover the full allelic spectrum of causal 
polymorphisms and thereby obtain the most precise quan-
tification of the genetic effects attributable to each locus. 
The part played by nonadditive interactions between dif-
ferent genetic loci and between susceptibility variants and 
environmental exposures (see below) needs to be charted, 
and discovery and replication studies need to be extended 
beyond the European populations that have been the focus 
of much of the current research.
 Heterogeneity 
 In general, a single polymorphism or mutation in a 
disease gene may lead to a more or less pronounced down-
regulation (or in rare cases upregulation) of the function 
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or amount of the corresponding gene product, which per 
se is sufficient for induction of the corresponding patho-
genic pathway ( fig. 4 ). Additional polymorphisms or mu-
tations in other genes or environmental factors are not 
required. This explains the relatively homogeneous phe-
notype of monogenic diseases, such as leprechaunism 
and MODY. In contrast, a single polymorphism in a sus-
ceptibility gene, which typically is accompanied by a 
rather moderate reduction (or in rare cases elevation) of 
the function or amount of the corresponding gene prod-
uct, per se is not adequate for triggering the disease phe-
notype ( fig. 7 ). The participation of additional polymor-
phisms in other genes and/or specific environmental 
 factors is required. In combination, this results in the 
complex polygenic inheritance of common diseases, 
which does not follow the mendelian laws. Thus suscep-
tibility genes apparently form the ‘gray zone’ ( fig. 7 , 
hatched areas) within the ‘gaussian’ distribution of the 
amount or function of the polymorphic gene product be-
tween the ‘healthy’ wild-type genes coding for (almost) 
normal gene products in the center of the curve, i.e. at the 
highest frequency, and the disease genes coding for more 
or less functionally impaired or overactive gene products 
on the flank of the curve, i.e. at lower frequency ( fig. 7 ). 
Moreover, as many of the causal polymorphisms are situ-
ated in noncoding regions of susceptibility genes, often at 
some distance from the coding sequence, they will often 
have subtle, spatially and/or temporally restricted effects. 
In such circumstances, gathering experimental evidence 
of their functional impact will be very difficult.
 As a consequence, a polymorphism in a single suscep-
tibility gene involved in glucose utilization and expressed 
in relevant tissues, such as the pancreas, muscle, fat, liver 
and intestinum will not be sufficient per se for induction 
of type 2 diabetes. In the example of  figure 7 , 5, 7 or 15% 
less functionality of beta cells, muscle or adipose cells 
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may still enable some glucose utilization, compatible with 
almost normal blood glucose homeostasis. Additional 
polymorphisms in the same or other tissues inherited 
from the parents or acquired in somatic cells during a 
lifetime are required to trigger the pathogenesis. Thus the 
combination of 5% (inherited) and 19% (acquired) func-
tional impairment in the beta cells, 7% in muscle cells and 
11 and 12% in beta cells or 15% in adipose cells and 19% 
in muscle cells may lead to diminished glucose utilization 
which over years fuels the development of type 2 diabetes. 
The situation is even more complex since polymorphisms 
or mutations in protective genes of tissues and organs in-
volved in glucose utilization may compensate for func-
tional weaknesses in the same or distinct tissues. Thus 15 
and 19% functional impairment of adipose and muscle 
cells may be overcome by 12% higher activity of ‘empow-
ered’ beta cells ( fig. 8 ). In fact, this compensatory mecha-
nism is operating in the majority of obese humans who 
would suffer from significantly impaired glucose utiliza-
tion by their muscle and liver cells in response to normal 
physiological insulin levels, i.e. from apparent peripheral 
insulin resistance. However, the elevated su pra phy siol-
ogical insulin secretion which can be maintained during 
the whole lifetime by the ‘empowered’ beta cells drives 
the adequate flux of glucose into peripheral tissues and 
thereby prevents the pathogenesis of type 2 diabetes. 
Only those obese subjects who lack ‘empowered’ beta 
cells will develop frank type 2 diabetes. Strikingly, differ-
ent polymorphisms of the same gene may play either a 
predisposing or a protective role, e.g. in the glucose-in-
duced apoptosis or in the glucose-induced proliferation/
differentiation of the beta cells.
 In conclusion, the manifestation of a huge number of 
combinations of the various susceptibility genes and their 
multiple polymorphisms in disease-relevant tissues is ap-
parent ( fig. 8 ). This explains the extraordinary genetic 
heterogeneity of common diseases, in general, and type 2 
diabetes, in particular. With the exception of monozy-
gotic twins, the probability for the identity of the genetic 
profile, i.e. specific combination of all the polymorphisms 
in the disease-relevant susceptibility genes, between 2 di-
abetic patients is almost zero. It seems to be very low even 
in 1st-degree relatives as exemplified by the following cal-
culation. Under the assumptions that a combination of 12 
homozygous polymorphisms in recessive susceptibility 
genes constitutes a complete causal pathogenic mecha-
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 Fig. 8. Concerted actions of inherited and 
acquired polymorphisms, as well as posi-
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nism (see below) and that only the mother or the father is 
a carrier of this combination and suffers from the disease, 
the probability for inheritance of exactly this combina-
tion is 0.5 12 = 0.024 %, or 0% in case of the other parent 
being a heterozygous carrier of each of the 12 polymor-
phisms or a noncarrier of even only one (or several) of 
these polymorphisms.
 Environment 
 Glucose disposal and its control by the relevant tissues 
are not only determined by the individual genetic profile. 
Negative and positive factors contributed by the environ-
ment modulate the function of the glucose-utilizing or-
gans as well. In a ‘positive’ environment, even numerous 
but functionally moderate polymorphisms, such as 15 
and 19% reduced activities in adipose and muscle cells, 
respectively, may not be sufficient to induce the patho-
genesis ( fig. 8 ). However, a ‘negative’ environment fur-
ther impairs the functionality of the same or different 
relevant tissues, by 8, 5 or 16% in adipose, beta cells or 
muscle cells, respectively, which, together with the mar-
ginally reduced beta cell activity (by 5%) caused by the 
polymorphism, will induce the pathogenesis ( fig. 8 ). For 
type 2 diabetes, the impact of the environment is most 
dramatic with regard to the individual lifestyle, in par-
ticular, nutrition and physical exercise. With increasing 
body weight as is reflected in the increase in the BMI, the 
deposition and accumulation of fat in the adipose tissue, 
and not only there, but also and even more so in other 
tissues, such as muscle, liver and beta cells, is accelerated 
( fig. 9 ). In order to prevent excessive storage of neutral 
lipids, those cells respond with downregulation of the in-
sulin-stimulated glucose uptake and metabolism, which 
provide essential building blocks for lipid synthesis, by 
molecular mechanisms, which are not yet fully under-
stood. The resulting ‘physiological’ insulin resistance 
with impaired glucose disposal predominantly in muscle 
and liver tissues leads to impaired glucose tolerance, i.e. 
steep increase in blood sugar after food consumption 
( fig. 1 ), which via a stage of prediabetes (with HbA1c lev-
els below a critical threshold) proceeds to full-blown type 
2 diabetes ( fig. 9 ). Importantly, the disease-relevant cells 
and tissues of different individuals (patients A and B in 
 fig. 9 ) may respond to the same negative environmental 
factors (development of BMI) with the same (lipid depo-
sition in muscle) and/or different (muscle glucose dispos-
al) sensitivity, which is also determined by susceptibility 
genes. This explains the well-known observations that 
despite identical lifestyle some patients (here A) will pass 
the state of prediabetes and develop frank type 2 diabetes 
at a considerably earlier time point than others (here pa-
tient B). This reflects the heterogeneity of the inherited 
and acquired polymorphisms in susceptibility genes 
which control the sensitivity of tissues relevant to glucose 
utilization (here muscle) leading to the deposition of neu-
tral lipids.
 The impact of environmental factors on the glucose-
utilizing organs may be positive as well. In the example 
of  figure 7 , the functionality of adipose cells, which would 
be reduced by 16% due to a polymorphism in a suscepti-
bility gene, becomes fully restored by appropriate nutri-
tion and thereby counteracts the development of type 2 
diabetes, although the functional impairment (by 15%) of 
the muscle cells persists. Thus, susceptibility genes and 
environmental factors in close cooperation contribute to 
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the considerable heterogeneity in the individual patho-
genic developments of type 2 diabetes, in particular, and 
common diseases, in general.
 Evolution 
 It is evident that, as a result of the intimate relationship 
between biological and cultural evolution, natural selec-
tion favored the spread of polymorphisms and mutations 
with moderate impact on the amount and/or function of 
the corresponding gene products that are associated with 
significant advantages for survival and vitality during 
certain periods of mankind. A plausible explanation for 
the interaction between genes and environment during 
the pathogenesis of type 2 diabetes is provided by the 
‘thrifty-gene hypothesis’. According to Neel  [42] , the 
probability of survival of individuals living in an envi-
ronment with unsteady nutrient supply, i.e. of our hunt-
ing and gathering ancestors during periods of famine, 
was higher with the greater capacity for energy storage 
during periods of nutrient abundance. Energy storage is 
much more efficient as deposition of neutral lipids, pref-
erably in the abdominal rather than subcutaneous adi-
pose tissue compared to glycogen storage in muscle and 
liver tissues. The observed early accumulation of abdom-
inal adipose tissue in 1st-degree relatives of type 2 dia-
betic patients may thus be interpreted as the result of nat-
ural selection for carriers of genes that guarantee efficient 
energy storage and, as a prerequisite, utilization of the 
glucose taken up by food. Relevant genes may trigger ex-
cessive insulin secretion by beta cells in response to food 
uptake in parallel to those provoking transient ‘physio-
logical’ insulin resistance of muscle and liver cells, but 
leaving unaltered the insulin sensitivity of adipose cells. 
Thereby, the food calories are efficiently taken up and 
predominantly stored in the adipose tissue in the long 
term without the danger of hypoglycemia in the course 
of immediate disposal of the blood glucose by muscles 
and the liver. Importantly, the continuous changes be-
tween nutrient abundance and deprivation as were typi-
cal for hunters and gatherers prevented the development 
of a permanent ‘pathological’ insulin resistance and the 
excessive accumulation of lipids and, as a consequence, 
the development of obesity. In the course of the neolithic 
revolution, with the invention of agriculture and farming 
and subsequent industrialization in the Western world, 
this advantage of the ‘physiological’ insulin resistance in 
combination with hyperinsulinemia, i.e. supraphysiolog-
ical plasma insulin levels, was blunted. The permanent 
and excessive availability of food with high calorie con-
tent reversed the former advantage for survival into a dis-
advantage. In conclusion, according to the thrifty-gene 
hypothesis, complex combinations of polymorphisms 
and mutations in genes controlling metabolic pathways 
which facilitated the survival of our ancestors increase 
the susceptibility of the present population to the devel-
opment of type 2 diabetes.
 The ‘thrifty-phenotype hypothesis’ provides an alter-
native explanation for the intimate interplay between 
genes and the environment. According to Hales and 
Barker  [43] , intrauterine malnutrition leads to delayed 
and impaired development of the molecular mechanisms 
of glucose utilization and energy storage, i.e. of an effi-
cient action of insulin in muscle, liver and adipose tis-
sues, insulin production and secretion by the beta cells as 
well as glucose sensing by beta cells and intestinal cells. 
During later life, calories taken up in excess will not be 
handled properly by concerted actions of these cells and 
will not be deposited in the adipose tissue, exclusively, but 
will be stored as lipid in muscle and liver, as well. This 
bypass further drives impaired glucose utilization and 
development of type 2 diabetes into a vicious circle. For 
the malnourished embryo, the diminished insulin-de-
pendent glucose utilization is of advantage since it allows 
the rapid access to calories contained in the limited 
amount of food available to meet the short-term energy 
requirements. In conclusion, the thrifty-phenotype hy-
pothesis attributes the susceptibility genes a special role 
in determining the sensitivity of beta cells, muscle, liver, 
adipose and intestinal cells for rapid energy mobilization 
during intrauterine malnutrition.
 Predictive Value 
 The complex interplay between polymorphisms in a 
multitude of susceptibility genes (each with a relatively 
moderate functional impact, i.e. effect size) and a broad 
array of environmental factors results in a huge number 
of theoretically possible combinations which ultimately 
reflect the causal chains of events, i.e. pathogenic mech-
anisms leading to common multifactorial diseases, such 
as type 2 diabetes. According to Rothman and Green-
land  [35] , the understanding of a complete causal patho-
genic mechanism provides a combination of the condi-
tions, events or (single) components (at the physiological 
and/or molecular level) sufficient and necessary for the 
devel opment of the disease. Thus, this combination will 
inevitably trigger the pathogenesis. Consequently, if all 
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the components constituting a pathogenic mechanism 
are present, the disease risk is 100%, and if one or sev-
eral components are missing, the risk is 0%. Chance or 
indetermination does not play a role in this model of the 
complete causal pathogenesis. However, most complex 
common diseases rely on several or many distinct com-
plete causal pathogenic mechanisms which often inter-
act in complex fashion. The resulting ‘nonlinearity’ of 
the pathogenesis in time and space (i.e. tissue) makes it 
often very difficult to decipher the causal chain of 
events.
 The elucidation of a complete causal pathogenic 
mechanism for a common disease necessitates the selec-
tion of a specific combination of single components from 
the multitude of theoretically possible combinations 
which inevitably lead to the pathogenesis. This is a tre-
mendous scientific challenge. For the reasons mentioned 
above, the number of possible combinations is extremely 
high and typically by far exceeds the number of pro-
bands even of large association studies. In case of the si-
multaneous analysis of 12 susceptibility genes with 3 
polymorphisms each, the number of possible combina-
tions accounts for 3 12 = 531,441. Consequently, in a large 
study encompassing 30,000 probands, each possible 
combination including that of healthy controls will be 
detected only once at best, even if certain pathogenic 
mechanisms, i.e. combinations, occur at a higher fre-
quency than others. The consequences for the prognosis 
and diagnosis as well as the therapy of common diseases 
are severe  [32] . It will remain difficult to finally prove by 
association (i.e. linkage analysis or linkage disequilibri-
um, see above) that a certain combination of polymor-
phisms in relevant susceptibility genes that have been de-
tected in affected probands only, constitutes a complete 
causal pathogenic mechanism. In fact, the probability of 
finding a specific combination once identified in more 
than one proband is extremely small. Furthermore, the 
value of the identification of a unique combination of 
polymorphisms in susceptibility genes for the prediction 
of a common disease is rather low. This holds true even 
under the prerequisite of the successful demonstration 
that it defines a complete causal pathogenic mechanism. 
Only very few (if any) humans share the identical or a 
very similar genetic profile with the affected individual 
from whom the specific combination has been original-
ly derived.
 For these reasons, it seems unlikely that large or very 
large numbers of identified susceptibility genes would 
significantly increase the predictive power for type 2 dia-
betes compared to the traditional risk factors, such as age, 
sex, BMI, fasting blood glucose. Thus, the 100% predic-
tive value typical for monogenic diseases (e.g. Hunting-
ton’s chorea), will probably never be reached for common 
diseases ( fig. 10 ). This is exemplified best by the observa-
tion that certain combinations of 3 and 14 out of the hith-
erto demonstrated susceptibility genes for type 2 diabetes 
( fig. 6 ) increase the disease risk from 50% (probability of 
throwing a coin) only to 55 and 58%, respectively ( fig. 10 ). 
Strikingly, on the basis of traditional risk factors solely, 
type 2 diabetes is currently being predicted with about 
59% probability; upon combination with the 3 suscepti-
bility genes, this probability only increases to 61% ( fig. 10 ). 
Unfortunately, a number of polymorphisms in certain 
susceptibility genes for type 2 diabetes are likely to induce 
or modulate the development of these traditional risk fac-
tors or to affect their consequences for the disease pheno-
type. However, only those polymorphisms of susceptibil-
ity genes will improve the predictive value compared to 
traditional risk factors, which operate via hitherto un-
known pathogenic mechanisms and/or determine the ex-
pression of risk factors that have escaped detection and 
measurement so far. The likelihood for the operation of 
pathogenic mechanisms that have not been recognized so 
far will vary with certain subsets of common diseases 
rather than being uniform. This nourishes the hope that 
the predictive value of the genetic profile will increase 
50
60
70
80
90
100
Pr
ed
ic
ti
on
 o
f
di
se
as
e 
ri
sk
 (%
)
Combination
of polymorphisms
 (n)
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z  
K
C
N
J1
1
K
C
N
J1
1 
+ 
P
P
A
R
G
P
P
A
R
G
 +
 T
C
F7
L2
TC
F7
L2
K
C
N
J1
1
K
C
N
J1
1 
+ 
P
P
A
R
G
P
P
A
R
G
 +
 T
C
F7
L2
TC
F7
L2
    +
 1
111
A
ge
+S
ex
+B
M
I+
B
lo
od
Su
ga
r
A
ge
+S
ex
+B
M
I+
B
lo
od
Su
ga
r
+ 
K
C
N
J1
1
K
C
N
J1
1+
 P
P
A
R
P
P
A
R
G
 +
 T
C
F7
L2L2
1 2 3.14..49...276...4,952...10,341
H
un
ti
ng
to
n‘
s 
ch
or
ea ?
Var
ian
ce
H
TT
 / 
IT
15T1
5
Type
 2 dia
betes
 Fig. 10. Prediction of the risk for monogenic (Huntington’s 
 chorea) and polygenic diseases (type 2 diabetes) on basis of the 
combination (A to Z) and number of polymorphisms (1–10,341) 
in the relevant disease (huntingtin,  HTT/IT15 ) or susceptibility 
 (KCNJ11, PARG, TCF7L2) genes, respectively, as well as tradition-
al risk factors and biomarkers. BMI = Body mass index. 
Co
lo
r v
er
si
on
 a
va
ila
bl
e 
on
lin
e
 Müller Pharmacology 2010;85:168–187184
and diagnostic predictive power. This is true in particular 
for the determination of the proteins and metabolites at 
a very early time point in the pathogenesis (see below). 
Nevertheless, the predictive power typical for monogenic 
diseases will never be reached for common diseases, ir-
respective of the higher variance generally observed for 
common compared to monogenic diseases. In any case, 
the identification of novel pathogenic mechanisms and 
associated risk factors or biomarkers, such as proteins 
and metabolites, will represent an additional indepen-
dent and valuable outcome emerging from future GWA 
studies for susceptibility genes with improved predictive 
power.
upon the inclusion of an increasing number of ‘novel’ sus-
ceptibility genes involved in hitherto unknown patho-
genic mechanisms and approach the 100% value more 
closely than on the basis of the previously identified poly-
morphisms ( fig. 10 ).
 Importantly, proteins and metabolites, such as lipids, 
amino acids and metabolites, are ‘mechanistically closer’ 
to the pathogenic mechanism than the genes directly or 
indirectly controlling their synthesis. Therefore, analysis 
of the polymorphic patterns of proteins and metabolites 
reflecting the gene product variants – which directly or 
indirectly emerge from the expression of the correspond-
ing susceptibility genes – in the relevant tissues and se-
rum of probands may further enhance the prognostic 
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Personalized Prognosis and Diagnosis
 A number of susceptibility genes and polymorphisms 
associated with type 2 diabetes to a certain degree have 
been identified so far ( fig. 6 ). Nevertheless, the current 
diagnosis is exclusively relying on traditional risk fac-
tors, i.e. the serum parameters, fasting blood glucose and 
HbA1c, and is often restricted to routine medical exam-
inations in elderly probands ( fig. 11 ). However, at this late 
time point of diagnosis, most type 2 diabetic patients are 
already suffering from impaired glucose tolerance and 
even slightly to moderately elevated fasting blood glu-
cose levels, which per se are not associated with acute 
symptoms and pain, but have already set into motion the 
vicious pathogenic circle ultimately leading to late dia-
betic complications. Unfortunately, early symptoms, 
such as slight nerve pain, excessive thirst or deterioration 
of visual power, which often accompany the prediabetic 
stage, and moderately elevated HbA1c levels, are often 
being overlooked during routine medical examinations 
unless the patient is aware of familial clustering of type 
2 diabetes. Admittedly, the timely recognition of elevat-
ed levels of fasting blood glucose, plasma insulin and 
HbA1c as well as of peripheral insulin resistance and im-
paired glucose tolerance is not very demanding from a 
technical point of view or from the time frame available 
due to the long-lasting pathogenesis, which typically re-
quires years to decades from the states of impaired glu-
cose tolerance and pre-diabetes to frank type 2 diabetes. 
However, these parameters do not provide any informa-
tion about the complex etiology of the disease, which, as 
outlined above, differs from patient to patient. Some 
forms may have their origin in defective glucose sensing 
by the beta cells or intestinal cells, other forms in defec-
tive insulin production and secretion, and certain forms 
in defective insulin action in muscle, liver or adipose 
cells, and others may originate from combinations 
 thereof. However, this information is a prerequisite for 
personalized therapy addressing the pathways of glucose 
sensing, insulin production, insulin secretion or insulin 
action in the relevant target cells with its crucial advan-
tages in efficacy and safety if the primary cause of the 
disease is aimed at rather than (a multitude of) second-
ary consequences. Therefore, determination of the com-
plete gene, protein and  metabolite profiles covering all 
inherited and acquired polymorphisms in the relevant 
susceptibility genes and gene products could be helpful 
for an earlier and more reliable prognosis and diagnosis 
of type 2 diabetes with critical advantages for its preven-
tion and therapy ( fig. 11 ).
 This is exemplified in the pattern of small-molecule 
metabolites in glucose-utilizing tissues, such as muscle, 
as revealed by two-dimensional separation by capillary 
electrophoresis and liquid chromatography  [44, 45] . The 
patterns considerably differ between probands analyzed 
at the stage of prediabetes and frank type 2 diabetes with 
quantitative differences ranging from ‘black to white’ to 
‘dark gray to light gray’ ( fig. 11 ). The elucidation of the 
corresponding protein patterns, which is facilitated by 
modern protein chip technology  [46] , would reveal com-
parable differences. This challenging, seemingly ‘global’ 
approach, so-called systems biology, encompasses the 
analysis of all genes (genomics), proteins (proteo mics) 
and metabolites (metabolomics) with the aim of identify-
ing their quantitative changes in expression and their 
mutual relationships along time and space  [45, 46] . Early 
prognosis and diagnosis based on systems biology, which 
combines genomics, proteomics, metabolomics, tradi-
tional risk factors and novel biomarkers, may ensure the 
maximally possible predictive power ( fig. 11 ).
 However, it is not yet clear whether personalized in-
formation of this kind (particularly when other pertinent 
factors such as age, ethnicity, family history and BMI are 
not explicitly taken into account) will lead individuals 
toward beneficial changes in health-related behaviors 
 [47] or alterations in their clinical management. Indeed, 
if such information were to be poorly presented, there is 
a danger that overestimation of the deterministic quali-
ties of genetic information could motivate individuals 
 toward counterproductive changes in their lifestyle 
(through unwarranted fatalism or feelings of personal 
immunity). The final challenge lies in placing systems bi-
ology into a translational context. The clinical utility and 
validity of gene, protein and metabolite diagnostics have 
already been established in monogenic diseases, such as 
MODY, where such testing can influence clinical practice 
and treatment. It is a major challenge to establish how to 
use analogous knowledge from the identification of pre-
disposing polymorphisms of genes, proteins and metabo-
lites for common diseases such as type 2 diabetes, to im-
prove patient care. In the future, systems biology will be 
the prerequisite for an earlier and more reliable diagnosis, 
prognosis and therapy, tailored to the individual patho-
genic mechanism and thereby justify the hopes common-
ly associated with personalized medicine in the public 
 [37, 48–53] . No doubt, this necessitates a broad under-
standing of the putative personal consequences and ad-
vantages of systems biology-based diagnosis in the pub-
lic, which will critically depend on corresponding indi-
vidualized therapeutic options. It is clear from the daily 
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medical doctor’s experience and the increasing incidence 
of type 2 diabetes in all regions of the world with unlim-
ited access to calorie-rich diets that the mere offering of 
dietetic and exercise measures, albeit their benefits hold 
true for almost any common disease and individual, does 
not justify intensified efforts in personalized prognosis 
and diagnosis.
 Conclusions 
 Common or civilization diseases, such as type 2 dia-
betes, coronary heart diseases and degenerative diseases, 
are caused by a complex multifactorial interplay of genes 
and environmental factors. Recent developments in ge-
nomic sciences have led to the discovery of numerous dis-
ease and susceptibility genes. This nourished great hope 
in personalized medicine with its promise of reliable 
prognosis, early diagnosis as well as efficient and safe 
therapy of common diseases in the near future based on 
the determination of individual genetic profiles. Howev-
er, association and clinical studies have also revealed the 
rather limited predictive value of the current analysis of 
gene polymorphisms for common diseases, even if it is 
combined with that of traditional risk factors. However, 
there are good reasons for assuming that the detection of 
additional susceptibility genes in combination with the 
analysis of proteins, metabolites as well as traditional and 
novel biomarkers will improve the predictive value to the 
degree necessary and sufficient for a personalized prog-
nosis and diagnosis. Nevertheless, the considerable ex-
penditure for a personalized prognosis and diagnosis will 
be justified only in combination with the availability of a 
personalized therapy.
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